Pharmaceuticals, Biotechnology and Life Sciences
Former MedReleaf executive team joins Closner in transformative venture to drive cannabinoid fermentation efforts NEW YORK–(BUSINESS WIRE)–LAVVAN Inc. (“LAVVAN”) today…
– Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors – Successfully…
LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for…
Another successful outcome from a Versant-created company in a breakthrough field SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia…
Allows Propanc to Move to Pre-Validation Stage and Facilitate Discussion with Investigators at Peter Mac Center, Australia’s Largest Cancer Hospital…
Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019…
— Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Is Enrolling Rapidly — — Recent Data Supports Potential…
NYU School of Medicine will lead trials testing CBD treatment for patients with Alcohol Use Disorder and Post-Traumatic Stress Disorder…
Auryxia ® Revenue Increases to $29.1 Million for Q2’FY19, Up 21% from Q2’FY18 and Up 26% from Q1’FY19; ANDA Settlement…
— Initiated Phase 1 study of MGTA-145 first-line mobilization therapy, enrollment on track for data presentation before end of year…